SelectImmune: Introducing Hamlet BioPharma to investors
Hamlet BioPharma the innovative pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections today launches the new website introducing Hamlet BioPharma, providing a first overview of the company, recent transactions and the main projects.
A merger of HAMLET Pharma and SelectImmune Pharma was formally decided on May 17[th], 2023. The decisions were taken by extra general assemblies in the respective companies. The transaction also includes the acquisition of a tuberculosis project and a collaboration agreement with Linnane Pharma. The formal process of the merger is being initiated and the process of establishing Hamlet BioPharma is estimated to complete in August.
For more information, please see www.hamletbiopharma.com